Route 1
Psychiatry & evidence
What does clinical high risk mean? What can existing care offer? What have studies found, and which questions remain unanswered? Start with the clinical context, then explore the research.
Start with a question
Science
The clinical questions and the compounds being studied
Understanding our research means understanding two connected areas: the psychiatric conditions we are investigating, and the compounds and formulations being studied. Explore either route, then follow the evidence behind individual statements.
Two learning routes
Route 2
Understanding cannabinoids
Cannabis is a plant containing many compounds. CBD and THC are different molecules with different effects. Learn how compounds, products, formulations and clinical evidence fit together.
Start with a question
Our programme
NWPT-SM32300 is NWPharmaTech’s investigational 300 mg CBD micellar-emulsion softgel. The planned Phase 2B study is designed to evaluate dose response, symptoms, safety and tolerability, and inform the next stage of development.
Effectiveness in this population has not been established. General cannabinoid research does not establish that it is effective.
- NWPT formulationWhat the formulation is designed to do, what has been measured, and the open research question
- Programme RoomWhat has been studied, what is planned and what remains unknown
On the formulation page:
Continue
Programme updates are news only. They are not a financing form and they do not ask for health information.
Financing questions are a separate route on the Contact page. You cannot invest, pay, or connect a wallet on our website.